D-deoxyribose Hydrogel for Angiogenesis in Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomaterials for wound healing and hair restoration lack intrinsic vasculature, relying on blood vessel ingrowth from the underlying wound bed, which is inefficient and often ineffective, especially in extensive burns and chronic wounds, and existing treatments for hair loss are costly and unsustainable.
Innovation Solution
A biocompatible matrix material or hydrogel incorporating D-deoxyribose sugar, preferably 2-deoxyribose, is used to promote wound healing and hair regrowth by stimulating angiogenesis and vascularization, utilizing biodegradable carriers like electrospun scaffolds or crosslinked hydrogels that release the sugar to support new blood vessel formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF is added alone to promote angiogenesis, then angiogenic activity is enhanced, but the factor is rapidly broken down or diluted and washed away, reducing effectiveness
Solution Approach 1:
The patent uses heparin as an intermediary carrier to deliver VEGF. Heparin binds to VEGF and other pro-angiogenic factors, protecting them from rapid degradation and dilution. This mediator approach allows sustained release of VEGF at the wound site, resolving the contradiction between enhancing angiogenic activity and maintaining factor stability.
Solution Approach 2:
The patent incorporates VEGF and heparin into biomaterials (hydrogels, scaffolds, or particles) before application to the wound. This preliminary encapsulation or binding protects the growth factors from immediate degradation and ensures controlled release, addressing the stability issue before the factors can be broken down or washed away.
2Duration of action of stationary object
If VEGF is bound to biomaterials for sustained delivery, then stability and duration of action are improved, but the cost of treatment increases significantly
Solution Approach 1:
The patent replaces expensive VEGF with D-deoxyribose, a cheap and stable sugar molecule. While D-deoxyribose itself is not VEGF, it serves as an alternative angiogenic stimulus that achieves similar therapeutic goals without the high cost and instability of recombinant VEGF. This substitution dramatically reduces treatment cost while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent changes the chemical parameter of the angiogenic agent from a complex protein (VEGF) to a simple sugar (D-deoxyribose). This parameter change transforms the molecule from expensive and unstable to inexpensive and stable, while still achieving angiogenesis promotion through a different molecular mechanism.
3Device complexity
If blood vessel ingrowth from underlying wound bed is relied upon, then no additional vasculature is needed in the material, but wound healing is inefficient and often ineffective in extensive burns and chronic wounds
Solution Approach 1:
The patent incorporates pro-angiogenic factors (VEGF, heparin, or D-deoxyribose) into the biomaterial before implantation. This preliminary inclusion of angiogenic stimulants activates blood vessel formation from the surrounding tissue into the material, rather than waiting for passive ingrowth. This accelerates vascularization and improves wound healing efficiency in extensive burns and chronic wounds.
Data Source
AI summary
The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.